Evidence map›Paper›PMID 27236412›Full record

Trial reportBMC psychiatry2016

Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.

Yoshiteru Takekita, Yosuke Koshikawa, Chiara Fabbri, Shiho Sakai, Naotaka Sunada, Ai Onohara, Keiichiro Nishida, Masafumi Yoshimura, Masaki Kato, Alessandro Serretti and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04076371 (The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04076371 nacompletednot on this map

The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

TypeinterventionalSponsorBeijing HuiLongGuan HospitalRan2012 to 2018Enrolled1,640ConditionsSchizophreniaArmsolanzapine-sertraline combination, only olanzapine, risperidone-sertraline combination, only risperidone, paliperidone-sertraline combination
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Yoshiteru TakekitaDepartment of Biomedical and NeuroMotor Sciences, University of Bologna, Viale Carlo Pepoli 5, Bologna, 40123, Italy. takekity@takii.kmu.ac.jp.
Yosuke KoshikawaDepartment of Neuropsychiatry, Kansai Medical University, 10-15 fumizono-cho, Moriguchi-shi, Osaka, 570-8507, Japan.
Chiara FabbriDepartment of Biomedical and NeuroMotor Sciences, University of Bologna, Viale Carlo Pepoli 5, Bologna, 40123, Italy.
Shiho SakaiDepartment of Neuropsychiatry, Kansai Medical University, 10-15 fumizono-cho, Moriguchi-shi, Osaka, 570-8507, Japan.
Naotaka SunadaDepartment of Neuropsychiatry, Kansai Medical University, 10-15 fumizono-cho, Moriguchi-shi, Osaka, 570-8507, Japan.
Ai OnoharaDepartment of Neuropsychiatry, Kansai Medical University, 10-15 fumizono-cho, Moriguchi-shi, Osaka, 570-8507, Japan.
Keiichiro NishidaDepartment of Neuropsychiatry, Kansai Medical University, 10-15 fumizono-cho, Moriguchi-shi, Osaka, 570-8507, Japan.
Masafumi YoshimuraDepartment of Neuropsychiatry, Kansai Medical University, 10-15 fumizono-cho, Moriguchi-shi, Osaka, 570-8507, Japan.
Masaki KatoDepartment of Neuropsychiatry, Kansai Medical University, 10-15 fumizono-cho, Moriguchi-shi, Osaka, 570-8507, Japan.
Alessandro SerrettiDepartment of Biomedical and NeuroMotor Sciences, University of Bologna, Viale Carlo Pepoli 5, Bologna, 40123, Italy.
Toshihiko KinoshitaDepartment of Neuropsychiatry, Kansai Medical University, 10-15 fumizono-cho, Moriguchi-shi, Osaka, 570-8507, Japan.
Kansai Medical University · JPUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently, long-acting injection (LAI) of second-generation antipsychotics has become a valuable strategy for the treatment of schizophrenia. However, few studies have compared the effects of different LAI antipsychotics on cognitive functions so far. The present study aimed to compare the influence of risperidone LAIs (RLAI) and paliperidone palmitate LAIs (PP) on cognitive function in outpatients with schizophrenia.

methodsIn this 6-month, open-label, randomized, and controlled study, 30 patients with schizophrenia who were treated with RLAIs were randomly allocated to the RLAI-continued group or the PP group. At baseline and 6 months, the patients were evaluated using the Brief Assessment of Cognition in Schizophrenia (BACS) that was the primary outcome of the study. The Subjective Well-being under Neuroleptic drug treatment-Short form (SWNS), the Positive and Negative Syndrome Scale (PANSS), and the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) scores were secondary outcome variables and they were tested at the same time points.

resultsThe two groups did not differ in terms of PANSS, DIEPSS, or SWNS total score changes. However, the BACS score for the attention and processing speed item showed higher improvement in the PP group than the RLAI group (p = 0.039).

conclusionsThe results of this preliminary study suggest that PPs may improve attention and processing speed more than RLAIs. Anyway, a replication in a larger and double-blind study is needed.

trial registrationUMIN000014470 . Registered 10 July 2014.

Indexed as

AdultAntipsychotic AgentsCognitionDelayed-Action PreparationsDrug Administration ScheduleFemaleHumansInjections, IntramuscularIsoxazolesMaleMiddle AgedPaliperidone PalmitatePsychiatric Status Rating ScalesRisperidoneSchizophreniaTreatment OutcomeAntipsychotic AgentsDelayed-Action PreparationsIsoxazolesPaliperidone PalmitateRisperidoneCognitive functionEfficacyPaliperidone palmitateRisperidone long-acting injectionSchizophreniaSubjective well-being

Identifiers

PMID27236412
PMCPMC4884618
OpenAlexW2407135000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.